The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XXIV.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

Publications

Colbenson GA, Olson EM, Nelson DR

61-Year-Old Man With Shortness of Breath and Cough.

Mayo Clinic proceedings. 2021;96(8):2243-2247

Kalra SS, Chizinga M, Trillo-Alvarez C, Papierniak ES

Ustekinumab associated chronic eosinophilic pneumonia.

The Journal of asthma : official journal of the Association for the Care of Asthma. 2021;58(12):1670-1674

Brinker A, Cheng C, Chan V

Association of Noninfectious Pneumonia With Ustekinumab Use.

JAMA dermatology. 2019;155(2):221-224

Amy de la Bretèque M, Appere-De Vecchi C, Zeboulon C, Zaien I, Sigal ML, Mahé E

[Ustekinumab-induced eosinophilic pneumonia during the course of ustekinumab therapy for plaque psoriasis].

Annales de dermatologie et de venereologie. 2015;142(3):193-6

Yashiro M, Maejima H, Taniguchi T, Katsuoka K, Kimura M, Wada M

Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment.

European journal of dermatology : EJD. 2013;23(3):396-7